95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Chaokun Wang1Shuzhen Deng2Jing Chen1Xiangyun Xu1Xiaochen Hu1Dejiu Kong1
Gaofeng Liang2
Xiang Yuan1Yuanpei Li3*
Xinshuai Wang1*- 1Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China
- 2Medical College, Henan University of Science and Technology, Luoyang, China
- 3Department of Internal Medicine, UC Davis Comprehensive Cancer Center, University of California Davis, Sacramento, CA, United States
A Corrigendum on
The synergistic effects of pyrotinib combined with adriamycin on HER2-positive breast cancer
By Wang C, Deng S, Chen J, Xu X, Hu X, Kong D, Liang G, Yuan X, Li Y and Wang X (2021) Front. Oncol. 11:616443. doi: 10.3389/fonc.2021.616443
In the published article, there was an error in Figure 3 as published. Due to the large number of photos taken, careless naming errors led to the accidental reuse of some images. The corrected Figure 3 and its caption Figure 3. Effects of PYR and ADM on cell invasion appear below.
Figure 3
Figure 3. Effects of PYR and ADM on cell invasion. Cell invasion was analyzed with a Matrigel-coated Boyden chamber. SK-BR-3 and AU565 cells were treated with PBS, different concentrations of PYR (0.3, 3μg/ml), ADM (0.1, 0.3μg/ml) or a combination treatment(PYR+ADM) for 24 h. (A) Transwell invasion assays assessed the effect of PYR and ADM on SK-BR-3 cell invasion ability and histogram represents the statistical analysis. (B) Transwell invasion assays assessed the effect of PYR and ADM on AU565 cell invasion ability and histogram represents the statistical analysis. Original magnification was ×100. Data represent the mean ± S.D. of three independent experiments. *p<0.05 and **p<0.01 compared with the PBS group, #p<0.05 and ##p<0.01 compared with the combination group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: HER2 positive breast neoplasm, pyrotinib, adriamycin, synergistic, Akt
Citation: Wang C, Deng S, Chen J, Xu X, Hu X, Kong D, Liang G, Yuan X, Li Y and Wang X (2025) Corrigendum: The synergistic effects of pyrotinib combined with adriamycin on HER2-positive breast cancer. Front. Oncol. 15:1536374. doi: 10.3389/fonc.2025.1536374
Received: 28 November 2024; Accepted: 07 February 2025;
Published: 18 March 2025.
Edited and Reviewed by:
Sharon R. Pine, University of Colorado Anschutz Medical Campus, United StatesCopyright © 2025 Wang, Deng, Chen, Xu, Hu, Kong, Liang, Yuan, Li and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xinshuai Wang, eHNodWFpd0BoYXVzdC5lZHUuY24=; Yuanpei Li, bHlwbGlAdWNkYXZpcy5lZHU=